Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
Orchestra BioMed Holdings, Inc. announced its participation in the upcoming Piper Sandler 38th Annual Healthcare Conference.
Stocks · News reference
Orchestra BioMed announced it will host an R&D Day to provide clinical insights and development plans for its AVIM Therapy and Virtue® Sirolimus AngioInfusion™ Balloon.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Orchestra BioMed Holdings, Inc. announced its participation in the upcoming Piper Sandler 38th Annual Healthcare Conference.
An analyst has increased the price target for Orchestra BioMed Holdings, Inc. to $12.00 per share.
Orchestra BioMed announced its third-quarter 2026 financial results, highlighted the completion of enrollment for its BACKBEAT pivotal trial, and confirmed a cash runway extending through 2028.
Filed: 2026-11-09 AccNo: 0001104659-26-124502 Size: 587 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Orchestra BioMed Holdings, Inc. has priced an underwritten public offering of 15 million shares of its common stock at $5.00 per share.